2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The selective 5-HT6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the present study, our aim was to investigate whether the novel highly selective 5-hydroxytryptamine6 (5-HT6) receptor antagonist SLV can ameliorate impairments in cognition and social interaction with potential relevance for both schizophrenia and Alzheimer's disease (AD). SLV sub-chronically - treated Wistar rats reared in isolation showed significantly enhanced prepulse inhibition (PPI) and object recognition performance when compared to vehicle - treated rats. In the isolated rats, also a significant reduction in expression of hippocampal neural cell adhesion molecule polysialylation (NCAM-PSA) was found which was ameliorated following treatment with SLV (30mg/kg). The social engagement deficit in rats exposed in utero (on gestational day 12.5) to valproic acid (VPA) was reversed by treatment with SLV (30mg/kg). SLV (20 and 30mg/kg, p.o.) fully reversed MK-801 - induced deficits in the ORT and also scopolamine - induced deficits in both the Object Recognition Task (ORT) and Object Location Task (OLT) in Wistar rats. In addition, a combination of sub-optimal doses of SLV and donepezil attenuated scopolamine-induced ORT deficits. Furthermore, SLV (10mg/kg, p.o.) reversed spontaneous alternation deficits in the T-maze induced by MK-801 administration in Swiss mice and in aged C57Bl/6J mice. SLV additionally improved T-Maze spatial learning and passive avoidance learning in Sprague-Dawley rats with amyoid-beta (Aβ) injections into the hippocampus. In contrast, no benefits were found with SLV or the tested reference compounds (donepezil and RVT-101) on cognitive performance of 12months old Tg2576 mice. Also, in the social recognition task, an absence of cognitive enhancing properties was observed with SLV on "normal forgetting" in Wistar rats. Finally, analysis of spontaneous inhibitory postsynaptic currents (sIPSCs) frequency recorded from pyramidal cells revealed a reduction in the presence of 1μM of SLV. In conclusion, SLV was investigated in several rodent animal models and found to be effective at a least effective dose (LED) of 20mg/kg and 10mg/kg (p.o.) in the rat and the mouse, respectively.

          Related collections

          Author and article information

          Journal
          Neurobiol Learn Mem
          Neurobiology of learning and memory
          Elsevier BV
          1095-9564
          1074-7427
          September 2016
          : 133
          Affiliations
          [1 ] Abbott Healthcare Products BV (formerly Solvay Pharmaceuticals), C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands. Electronic address: natasja.debruin@gmail.com.
          [2 ] Abbott Healthcare Products BV (formerly Solvay Pharmaceuticals), C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands.
          [3 ] AbbVie Deutschland GmbH & Co. KG, Dept. of Pharmacology, Knollstr., 67061 Ludwigshafen, Germany.
          [4 ] Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, PO Box 616, 6200 MD Maastricht, The Netherlands.
          [5 ] Neurofit SAS, Bioparc, Parc d'Innovation, Boulevard Sebastien Brant, 67400 Illkirch, France.
          [6 ] Berand Ltd., NovaUCD, Belfield Innovation Park, University College Dublin, Dublin 4, Ireland.
          Article
          S1074-7427(16)30094-6
          10.1016/j.nlm.2016.06.020
          27344942
          Copyright © 2016 Elsevier Inc. All rights reserved.

          Comments

          Comment on this article